Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193294 | 0.94 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL238312 | 0.94 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL386229 | 0.94 | LMNA (0.68) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL10991364 | 0.91 | LMNA (0.53) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL23673156 | 0.86 | LMNA (0.65) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL7269036 | 0.86 | LMNA (0.74) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL10945252 | 0.86 | LMNA (0.74) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL3155312 | 0.86 | LMNA (0.48) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL27560161 | 0.84 | LMNA (0.70) | LMNABLMMEN1CYP3A4ALOX15 | |
| SCHEMBL10953541 | 0.84 | LMNA (0.70) | LMNABLMMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9882245-B2 | Alkoxide-based magnesium electrolyte compositions for magnesium batteries | UT-BATTELLE, LLC (US) | 2018-01-30 | — | — | US | disclosed |
| US-20160024421-A1 | IONIC LIQUIDS CONTAINING QUATERNARY PHOSPHONIUM CATIONS AND CARBOXYLATE ANIONS, AND THEIR USE AS LUBRICANT ADDITIVES | U.S. DEPARTMENT OF ENERGY | 2016-01-28 | — | — | US | disclosed |
| US-9149479-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20150056499-A1 | ALKOXIDE-BASED MAGNESIUM ELECTROLYTE COMPOSITIONS FOR MAGNESIUM BATTERIES | U.S. DEPARTMENT OF ENERGY | 2015-02-26 | — | — | US | disclosed |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | THE UNIVERSITY OF TOLEDO (US) | 2015-01-22 | — | — | US | disclosed |
| US-8557991-B2 | Process for preparing enantiomerically pure indolopyridines | 4SC AG (DE) | 2013-10-15 | — | — | US | disclosed |
| US-8288399-B2 | Medicine containing pyrimidine derivative | BTG INTERNATIONAL LIMITED (GB) | 2012-10-16 | — | — | US | disclosed |
| EP-2420489-A1 | Indolesulfonyl protecting groups for protection of guanidino and amino groups | Lonza Ltd (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | 4SC AG (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-2280942-A1 | INDOLESULFONYL PROTECTING GROUPS FOR PROTECTION OF GUANIDINO AND AMINO GROUPS | Lonza Ltd. (CH) | 2011-02-09 | — | — | EP | disclosed |
| WO-2000012501-A1 | BENZONAPHTHYRIDINE-N-OXIDES COMPRISING A PDE3 AND PDE4 INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-03-09 | — | — | WO | disclosed |
| WO-1999064414-A1 | BENZAMIDES WITH TETRAHYDROFURANYLOXY SUBSTITUTENTS AS PHOSPHODIESTERASE 4 INHIBITORS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999057118-A1 | NOVEL N-OXIDES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999057115-A1 | NOVEL BENZIMIDAZOLES AND BENZOXAZOLES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-11-11 | — | — | WO | disclosed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| US-5747539-A | Fluorine-containing benzoylguanidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-05-05 | — | — | US | disclosed |
| EP-0228959-B1 | AMINOSTYRYL COMPOUND, LEUKOTRIENE ANTAGONISTIC COMPOSITION CONTAINING THE SAME AS EFFECTIVE INGREDIENTS AND METHOD OF ANTAGONIZING SRS BY EMPLOYING THE SAME | MITSUBISHI KASEI CORPORATION (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4749701-A | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1988-06-07 | — | — | US | disclosed |
| EP-0228959-A2 | Aminostyryl compound, leukotriene antagonistic composition containing the same as effective ingredients and method of antagonizing SRS by employing the same | MITSUBISHI KASEI CORPORATION (JP) | 1987-07-15 | — | — | EP | disclosed |
| US-4338315-A | RHINOVIRUSES | ELI LILLY AND COMPANY (US) | 1982-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077404-A1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE INDOLOPYRIDINES | GRIK5, CYP3A5, GRK5 | LMNA 3580/4885BLM 4262/4885MEN1 1957/4885 |
| US-20150024037-A1 | Xenoantigen-Displaying Anti-Cancer Vaccines and Method of Making | CSGALNACT1, GALNT1, DPAGT1 | LMNA 1554/4885BLM 4662/4885MEN1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.